Arthritis Segment Bolsters Nonsteroidal Anti-Inflammatory Drugs (NSAID) Market Growth

According to our new research study on "Nonsteroidal Anti-Inflammatory Drugs (NSAID) Market Forecast to 2031 - Global Analysis - by Drug Class, Route of Administration, Indication, and Distribution Channel ", the market was valued US$ 24.82 billion in 2024 to US$ 38.38 billion by 2031; the market is expected to register a CAGR of 6.5%. The Nonsteroidal Anti-Inflammatory Drugs (NSAID) Market report emphasizes the trends prevalent in the global market, along with drivers and deterrents affecting its growth.

The rising prevalence of chronic pain and inflammatory disorders, and growing inclination towards NSAIDs as the primary choice for non-opioid pain management contribute to the growing Nonsteroidal Anti-Inflammatory Drugs (NSAID) Market size. However, the growing regulatory and development barriers hampers the growth of the market. Further, rising shift toward sustainability and biodegradable gloves are expected to bring new Nonsteroidal Anti-Inflammatory Drugs (NSAID) Market trends in the coming years.

Growing Inclination towards NSAIDs as Non-Opioid Pain Management Bolsters Nonsteroidal Anti-Inflammatory Drugs (NSAID) Market Growth

NSAIDs are progressively recognized for effectively alleviating pain while reducing the risk of dependency and side effects commonly linked to opioids. Consequently, more patients and providers are turning to these medications to address pain in a safer and more sustainable way. Clinical Practice Guidelines from the Centers for Disease Control and Prevention (CDC) published in 2022 recommend that general practitioners prioritize non-opioid treatments, including NSAIDs, for both acute and chronic non-cancer pain, unless opioids are clearly necessary. Non-opioid therapies can provide pain relief that is comparable to opioids for many common acute pain conditions, such as musculoskeletal injuries, headaches, dental pain, and arthritis. Many NSAIDs, including ibuprofen and aspirin, are available over the counter, making them an accessible first option for self-managing mild to moderate pain. Prescription versions are available for more severe or persistent pain, such as that experienced in rheumatoid arthritis or after surgery.

The shifting preference for NSAIDs is significantly driven by the alarming opioid crisis, which has prompted healthcare professionals to adopt safer and non-addictive alternatives for pain relief, particularly for pediatric and adolescent patients following outpatient surgeries, is noteworthy. In light of the opioid epidemic and concerns about potential abuse, clinicians are turning toward NSAIDs combined with acetaminophen as a first-line strategy, aiming to avoid opioids while maintaining effective pain relief. Ongoing research is focused on optimizing such non-opioid regimens to provide adequate analgesia with minimal side effects. For instance, the CARES for Kids study (Comparing Analgesic Regimen Effectiveness and Safety After Surgery for Kids) will be the first prospective, randomized, controlled trial-often regarded as the gold standard-in comparing the effectiveness and safety of opioid and non-opioid pain medications following common surgical procedures in adolescents and young adults. The Patient-Centered Outcomes Research Institute (PCORI) has approved nearly US$ 7 million in funding to support this study, which aims to provide research-based evidence in this area.

Thus, the increasing adoption of NSAIDs over opioids in clinical settings fuels the nonsteroidal anti-inflammatory drugs (NSAID) market growth.

The Nonsteroidal Anti-Inflammatory Drugs (NSAID) Market analysis has been carried out by considering the following segments: drug class, route of administration, indication, and distribution channel, and geography. Based on drug class, the market is segmented into nonselective NSAIDS and cox-2 selective NSAIDs. The nonselective NSAIDS segment held the largest nonsteroidal anti-inflammatory drugs (NSAID) market share in 2024 and is expected to register the highest CAGR during 2025-2031.

In terms of indication, the nonsteroidal anti-inflammatory drugs (NSAID) market is segmented into arthritis, migraine, ophthalmic diseases, and others. The arthritis segment dominated the nonsteroidal anti-inflammatory drugs (NSAID) market in 2024 and is anticipated to register the highest CAGR during 2025-2031.

NSAIDs, including prescription options of celecoxib and etoricoxib, and OTC NSAIDs such as ibuprofen, naproxen, and diclofenac, are available and are considered first-line treatment to manage arthritis pain and inflammation.

New innovations such as advanced drug delivery systems and new and improved formulations of NSAIDs fuel the growth of the market. In May 2023, Pharmacy researchers at the University of Connecticut developed a new technology for the long-term administration of NSAIDs. This innovative approach involves long-acting injectable implants that form in situ and are biodegradable, aimed at reducing or eliminating the common side effects associated with NSAIDs.

By route of administration, the nonsteroidal anti-inflammatory drugs (NSAID) market is classified into oral, injectable and topical. The oral segment held the largest share of the nonsteroidal anti-inflammatory drugs (NSAID) market in 2024 and is expected to register a higher CAGR during 2025-2031.

In terms of distribution channel, the nonsteroidal anti-inflammatory drugs (NSAID) market is segmented into hospital pharmacies, retail pharmacies and online channels. The retail pharmacies segment held the largest share of the nonsteroidal anti-inflammatory drugs (NSAID) market in 2024.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed across the globe. As per an article "Nonsteroidal Anti-inflammatory Drug (NSAID) Toxicity," published in September 2023, in the US, over 70 million NSAID prescriptions are written annually. When OTC usage is factored in, the US alone consumes more than 30 billion doses of NSAIDs each year.

In terms of geography, the Nonsteroidal Anti-Inflammatory Drugs (NSAID) market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America.

Nonsteroidal Anti-Inflammatory Drugs (NSAID) Market Share, by Distribution Channel, 2024 (%)

Source: The Insight Partners Analysis

The scope of the nonsteroidal anti-inflammatory drugs (NSAID) market report includes an assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. In terms of revenue, North America dominated the nonsteroidal anti-inflammatory drugs (NSAID) market share in 2024. According to the Migraine Statistics 2025 published by SingleCare, 35 million people in the US are affected by migraines, with the majority being between the ages of 35 and 45. NSAIDs, such as ibuprofen and naproxen, are commonly used to reduce inflammation and pain associated with migraines, and their accessibility, affordability, and proven effectiveness make them a go-to option for both patients and healthcare providers.

Companies operating in the Nonsteroidal Anti-Inflammatory Drugs (NSAID) market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the human microbiome market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com